Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCN-104
- Development stage
- Unknown
- Lead developer
- Scienture
- Administration
- Subcutaneous
01
Overview
SCN-104 is a drug-device combination product consisting of dihydroergotamine (DHE) mesylate delivered via a proprietary, multi-dose, disposable injection pen. Developed by Scienture Holdings (formerly TRxADE HEALTH) through its subsidiary Scienture, LLC, it is being developed via the 505(b)(2) regulatory pathway for the acute treatment of migraine headaches (with or without aura) and cluster headache episodes. The device is designed for subcutaneous self-injection, featuring a lower injection volume and shielded needles compared to traditional ampoule-based administration. SCN-104 acts as an agonist at serotonin 5-HT1D receptors to provide rapid relief of headache symptoms by inducing vasoconstriction and inhibiting neurogenic inflammation.
- Other names
- dihydroergotamine mesylate injection pen
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR1F (Serotonin 5-HT1F receptor)
Beyond the preview
Go deeper on SCN-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCN-104.